Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Sawicki, PT; Siebenhofer, A.
Betablocker treatment in diabetes mellitus.
J Intern Med. 2001; 250(1):11-17
Doi: 10.1046%2Fj.1365-2796.2001.00829.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Siebenhofer-Kroitzsch Andrea
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES: Betablockers have been convincingly shown to reduce total and cardiovascular morbidity and mortality of hypertensive diabetic patients. In diabetic patients, after myocardial infarction, these agents confer a twice as high protective effect when compared to non-diabetic patients. However, most paradoxically, betablocking agents are used less frequently in diabetes. Control of hypertension is insufficient in most of the diabetic patients, probably because a combination of antihypertensive agents including betablockers is frequently needed to sufficiently control blood pressure but is not used in these patients. The fear of betablocker-associated side effects in diabetes may be partly responsible for the frequent antihypertensive mono-therapy and the resulting poor quality of blood pressure control among diabetic patients. DESIGN: We have performed an analysis of the literature to assess whether possible adverse metabolic effects, a higher risk of hypoglycaemia or less nephroprotective effects of beta1-selective betablocking agents could justify the reticence in prescribing these antihypertensive agents to diabetic patients. RESULTS: A thorough review of the literature does not indicate that beta1-selective betablocking agents have important adverse effects on glucose metabolism, prolong hypoglycaemia or mask hypoglycaemic symptoms. In diabetic nephropathy, betablockers are as nephroprotective as angiotensin converting enzyme inhibitors. CONCLUSIONS: The unnecessary less frequent prescription of beta1-selective betablockers in diabetes mellitus may contribute to the higher cardiovascular mortality among these patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adrenergic beta-Antagonists - administration and dosage
- Blood Glucose - metabolism
- Diabetes Complications - metabolism
- Diabetes Mellitus - blood
- Humans - blood
- Hypertension - blood
- Hypoglycemia - blood
- Receptors, Adrenergic, beta-1 - antagonists and inhibitors
- Risk - antagonists and inhibitors
- Find related publications in this database (Keywords)
- antihypertensive therapy
- beta blockers
- blood pressure control
- coronary heart disease
- diabetes mellitus
- glucose metabolism
- hypoglycaemia